[177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report
The [<sup>177</sup>Lu]Lu-PSMA radioligand therapy is a prostate-specific membrane antigen (PSMA) targeting treatment approved for patients with metastatic castration-resistant prostate cancer, after failure of androgen deprivation therapy or taxane-based chemotherapy. We report a unique case of a patient with metastatic hormone-sensitive prostate cancer (mHSPC) who received PSMA radioligand therapy as the sole treatment, without any prior or additional systemic treatment. Over a span of 8 years, the patient underwent 12 cycles of [<sup>177</sup>Lu]Lu-PSMA radioligand therapy, demonstrating favorable therapeutic response and a prolonged androgen deprivation therapy-free period. This case highlights the potential of long-term PSMA radioligand therapy as a standalone option in selected mHSPC patients.
Authors
- Sazan Rasul (ORCID: https://orcid.org/0000-0003-2898-3232)
- Elisabeth Kretschmer‐Chott
- Stefan Schmitl
- Gero Kramer (ORCID: https://orcid.org/0000-0003-1982-6817)
- Shahrokh François Shariat (ORCID: https://orcid.org/0000-0002-6627-6179)
- Marcus Hacker (ORCID: https://orcid.org/0000-0002-4222-4083)
- Ilva Kristiana Langrate
Institutions
- University of Jordan (JO)
- Cornell University (US)
- Charles University (CZ)
- Comprehensive Cancer Center Vienna (AT)
- Karl Landsteiner Society (AT)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Wiener klinische Wochenschrift
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1007/s00508-025-02642-3
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00